Fulvestrant injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, had a market value of approximately $550 million for the 12 months ended June 30.
The Prevacid 24HR brand and generic had a market value of approximately $57 million for the most recent 12 months ended August 2019, according to IQVIA.
Patients have lost nearly $10 billion in potential biosimilar savings since 2015 due to delayed launches, according to a new white paper from the Biosimilars Council, a division of the Association for Accessible Medicines.